Head to head
AbCellera Biologics vs Vertex Pharmaceuticals
Side-by-side on the measures that matter, with a plain-English read. Full detail: ABCL · VRTX
ABCL
AbCellera Biologics
9.69-7.45%
1-year price shape — +184% over the period
Quant Rating C · 99/100
vs
VRTX
Vertex Pharmaceuticals
515.02-1.08%
1-year price shape — +22% over the period
Quant Rating C · 68/100
1-year performance, rebased to 100
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals earns the most per share.
| ABCL | VRTX | |
|---|---|---|
| Snapshot | ||
| Sector | Biotechnology | Biotechnology |
| Last price | 9.69 | 515.02 |
| Change today | -7.45% | -1.08% |
| 1-year return | +184.2% | +22.0% |
| Market cap | $3.16B | $130.58B |
| 52-week range | 2.75 – 15.02 | 412.27 – 568.67 |
| Valuation | ||
| P/E (TTM) | -20.19 | 33.14 |
| P/E percentile, own 5-yr range | 6th | 99th |
| P/B | 2.98 | 6.25 |
| Dividend yield | 0.00% | 0.00% |
| Profitability & growth | ||
| EPS (TTM) | -0.49 | 15.32 |
| Net profit (TTM) | $-160.04M | $3.88B |
| Revenue (TTM) | $67.86M | $12.95B |
| Provider revenue period date | 2026-09-29 | 2026-09-29 |
| Revenue growth (YoY) | +18.8% | +11.8% |
| Gross margin | 100.0% | 85.5% |
| Operating margin | -275.7% | 33.1% |
| Net margin | -218.6% | 30.7% |
| Free cash flow (TTM) | $-32.85M | $3.20B |
| Provider cash-flow period date | 2026-09-29 | 2026-09-29 |
| Ownership & sentiment | ||
| Institutional ownership | 37.2% | 96.8% |
| Insider activity (12mo) | 45 buy / 4 sell | 28 buy / 22 sell |
| Short interest (% of float) | 9.0% | 1.9% |
| Analyst consensus | 89% buy / 11% hold (9) | 95% buy / 5% hold (21) |
| Analyst price target | $19 (+99%) | $624 (+21%) |
| StockVane view | ||
| StockVane Quant Rating | C (99) | C (68) |
| Company | ||
| Employees | 562 | 6,400 |
| Founded | 2012 | 1989 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.